Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...

Atherosclerosis I: Introduction

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...

Inflammation

Inflammation

Coronary Artery Disease IV: Preventive Measures

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Comparing incidence of heart failure in individuals with enlarged cardiac chambers versus diabetes.

American journal of preventive cardiology·2026

Same author

AI-quantified Myosteatosis at CAC CT for Prediction of Atrial Fibrillation and Heart Failure: The Multi-Ethnic Study of Atherosclerosis.

Radiology. Cardiothoracic imaging·2026

Same author

LL-37 IgG levels are associated with clinical characteristics and T follicular cell response in acute coronary syndrome in adults.

Physiological reports·2026

Same author

Adaptive immune response to the autoantigen LL-37 differentiates atherosclerotic cardiovascular disease phenotypes.

Clinical & translational immunology·2026

Same author

AI-Derived LA Volume Index, LA/RA and LA/LV Volume Ratios From Coronary Artery Calcium Scans Predict Long-Term Atrial Fibrillation and Stroke.

Stroke·2026

Same author

Modulating adaptive immunity by targeting plaque macrophages to reduce atherosclerosis progression.

European heart journal·2026

Search research articles

Related Experiment Video

Updated: May 31, 2026

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

Progress in HDL-based therapies for atherosclerosis.

Kuang-Yuh Chyu¹, Anish Peter, Prediman K Shah

¹Division of Cardiology and Oppenheimer Atherosclerosis Research Center, Cedars Sinai Heart Institute, Cedars Sinai Medical Center, Suite 5531, 8700 Beverly Blvd, Los Angeles, CA 90048, USA.

Current Atherosclerosis Reports

|July 12, 2011

Summary

Atherosclerosis, a chronic inflammatory artery disease, often leads to serious events like heart attack or stroke. Emerging therapies focus on high-density lipoprotein (HDL) to manage residual risk and improve outcomes.

More Related Videos

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Related Experiment Videos

Last Updated: May 31, 2026

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Area of Science:

Cardiovascular Medicine
Inflammation Research
Pharmacology

Background:

Atherosclerosis is a chronic inflammatory disease of medium and large arteries.
It arises from genetic and environmental factors like dyslipidemia, hypertension, diabetes, and smoking.
Severe outcomes, including myocardial infarction and stroke, stem from thrombosis on disrupted plaques.

Purpose of the Study:

To review new and emerging high-density lipoprotein (HDL)-based therapeutic strategies for atherosclerosis.
To address the persistent residual risk in atherosclerosis management despite current treatments.
To explore novel approaches beyond low-density lipoprotein (LDL) cholesterol reduction.

Main Methods:

Literature review of current research on HDL-based therapies.
Analysis of emerging pharmacological and lifestyle interventions targeting HDL.
Focus on strategies aimed at raising HDL levels or enhancing HDL function.

Main Results:

Current pharmacologic approaches, primarily statins, reduce LDL but leave significant residual risk.
High-density lipoprotein (HDL) plays a crucial role in reverse cholesterol transport and possesses anti-inflammatory properties.
Emerging strategies aim to increase HDL levels or improve its atheroprotective functions.

Conclusions:

Despite advances in LDL reduction, residual risk in atherosclerosis necessitates novel therapeutic targets.
High-density lipoprotein (HDL)-based therapies represent a promising frontier for managing atherosclerosis.
Further research into HDL-raising and HDL-function-enhancing strategies is critical for improving patient outcomes.